Aplitabart Biosimilar – Anti-TRAILR2 mAb – Research Grade

Description of Aplitabart Biosimilar - Anti-TRAILR2 mAb - Research Grade

Introduction

Aplitabart Biosimilar – Anti-TRAILR2 mAb is a therapeutic antibody that specifically targets the TRAILR2 protein. This biosimilar is a research grade version of the anti-TRAILR2 monoclonal antibody and is used for various scientific studies and research purposes. In this article, we will discuss the structure, activity, and applications of Aplitabart Biosimilar – Anti-TRAILR2 mAb in detail.

Structure of Aplitabart Biosimilar – Anti-TRAILR2 mAb

Aplitabart Biosimilar – Anti-TRAILR2 mAb is a monoclonal antibody that is produced by recombinant DNA technology. It is a humanized antibody, meaning that it is derived from non-human sources but has been modified to be more similar to human antibodies. The antibody is composed of two heavy chains and two light chains, which are held together by disulfide bonds.

The heavy chains are made up of constant and variable regions. The constant region is responsible for the effector functions of the antibody, while the variable region determines the specificity of the antibody for its target. The light chains also have constant and variable regions, with the variable region being responsible for binding to the target protein.

Aplitabart Biosimilar – Anti-TRAILR2 mAb has a molecular weight of approximately 150 kDa and a half-life of around 21 days in humans. It is stable at refrigerated temperatures and can be stored for extended periods without losing its activity.

Activity of Aplitabart Biosimilar – Anti-TRAILR2 mAb

The main activity of Aplitabart Biosimilar – Anti-TRAILR2 mAb is its ability to bind to the TRAILR2 protein. TRAILR2, also known as death receptor 5 (DR5), is a cell surface receptor that is involved in the regulation of apoptosis (programmed cell death). When Aplitabart Biosimilar – Anti-TRAILR2 mAb binds to TRAILR2, it activates the receptor and triggers a signaling cascade that leads to apoptosis of the target cell.

This activity of Aplitabart Biosimilar – Anti-TRAILR2 mAb has been extensively studied and has shown promising results in various preclinical and clinical trials. It has been found to be effective in inducing apoptosis in cancer cells, making it a potential therapeutic agent for cancer treatment. Additionally, Aplitabart Biosimilar – Anti-TRAILR2 mAb has also shown anti-inflammatory and immunomodulatory effects, making it a promising candidate for the treatment of various inflammatory and autoimmune diseases.

Applications of Aplitabart Biosimilar – Anti-TRAILR2 mAb

Aplitabart Biosimilar – Anti-TRAILR2 mAb has a wide range of applications in the field of scientific research. Its main use is in the study of apoptosis and the TRAILR2 signaling pathway. It is also used in various cancer research studies to investigate its potential as a therapeutic agent for different types of cancer.

Moreover, Aplitabart Biosimilar – Anti-TRAILR2 mAb is also used in the development of diagnostic assays for TRAILR2 and its associated signaling molecules. It can also be used in the development of biosensors for the detection of TRAILR2 in biological samples.

Another important application of Aplitabart Biosimilar – Anti-TRAILR2 mAb is in drug discovery and development. Its ability to induce apoptosis in cancer cells makes it a valuable tool for screening potential anti-cancer drugs. It can also be used in combination with other therapeutic agents to enhance their effectiveness.

Conclusion

Aplitabart Biosimilar – Anti-TRAILR2 mAb is a research grade therapeutic antibody that specifically targets the TRAILR2 protein. Its structure,